Robert E. Claypoole - 11 Jan 2024 Form 4 Insider Report for Bioventus Inc. (BVS)

Role
President and CEO, Director
Signature
/s/ Anthony D'Adamio, Attorney-in-Fact
Issuer symbol
BVS
Transactions as of
11 Jan 2024
Net transactions value
$0
Form type
4
Filing time
12 Jan 2024, 16:52:30 UTC
Previous filing
12 Jan 2024
Next filing
13 Jan 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BVS Restricted Stock Units Award $0 +375,000 $0.000000 375,000 11 Jan 2024 Class A Common Stock 375,000 Direct F1, F2
transaction BVS Stock Option (Right to Buy) Award $0 +850,000 $0.000000 850,000 11 Jan 2024 Class A Common Stock 850,000 $4.89 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of Class A common stock.
F2 The restricted stock units and options, as applicable, shall vest in four equal installments on each of the first four anniversaries of January 10, 2024, in each case subject to the Reporting Person continuing in service through the applicable vesting date.